文献速递肾移植肾小球疾病

非典型溶血性尿毒症综合征肾移植患者补体失调的体外试验:一项初步研究

Ex Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study.
PubMed 文献 · Kidney Int Rep · 2023-10-13

该初步研究将13例未接受依库珠单抗预防且处于缓解期的aHUS肾移植患者与13例其他原发性肾病肾移植患者进行盲法补体试验比较。结果显示两组在内皮细胞上的C5b-9沉积无显著差异,部分患者沉积升高但无血栓性微血管病实验室证据,且5例携带遗传变异的aHUS患者活化内皮细胞上C5b-9未见增加。作者质疑该体外补体试验在肾移植患者中的常规应用价值。

要点

  • aHUS与对照组肾移植患者的内皮细胞C5b-9沉积无显著差异。
  • 部分患者C5b-9沉积升高但无血栓性微血管病实验室证据。
  • 携带遗传变异的aHUS患者活化内皮细胞上C5b-9未见增加。

核心结论

  • 数据质疑体外补体试验在肾移植患者中的常规使用。
  • 未来研究应评估该试验在肾移植患者中的检测特征。

研究设计与样本

  • 初步研究纳入13例未接受依库珠单抗且处于缓解期的aHUS肾移植患者和13例其他原发性肾病肾移植对照。
  • 血清样本盲法评估内皮细胞上C5b-9沉积的补体试验。

主要发现

  • aHUS组与对照组静息细胞C5b-9沉积中位数分别为136%(范围93%-382%)和121%(范围75%-200%),无显著差异。
  • 活化细胞C5b-9沉积中位数分别为196%(范围99%-388%)和170%(范围113%-260%),无显著差异。
  • 3例aHUS患者和4例对照静息细胞C5b-9沉积升高,但均无血栓性微血管病实验室证据。
  • 随访15.8个月(范围6-21)期间所有患者估算肾小球滤过率保持稳定。
  • 5例携带遗传变异的aHUS患者活化内皮细胞上C5b-9沉积未增加。

临床怎么用

  • 提示不宜常规使用该体外补体试验监测肾移植后aHUS患者。
  • 对无依库珠单抗预防的aHUS肾移植患者,需结合临床和实验室综合评估。

局限性

  • 为初步研究,样本量小(aHUS组13例,对照组13例)。
  • 随访时间有限(中位15.8个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2014, a complement assay, which evaluates C5b-9 deposition on endothelial cells, was proposed as a biomarker for atypical hemolytic uremic syndrome (aHUS). Early diagnosis and/or prediction of aHUS (relapse) is pivotal in aHUS kidney transplant recipients who do not receive eculizumab prophylaxis. METHODS: In this pilot study, serum samples of transplanted patients with aHUS in remission without eculizumab and patients with other primary kidney diseases (controls) were blinded and evaluated in the complement assay. RESULTS: We included 13 patients with aHUS (4 males, 9 females) of median age of 54 years (range: 35-69) and median of 5.9 years (range: 0.25-14.1) after transplantation; and 13 controls (7 males, 6 females) of median age of 42 years (range: 27-60) and median of 5.8 years (range: 1.6-11.7) after transplantation. There were no significant differences in C5b-9 deposits between patients with aHUS and controls on resting cells (median of 136% [range: 93%-382%] and 121% [range: 75%-200%], respectively) and activated cells (median of 196% [range: 99%-388%] and 170% [range: 113%-260%], respectively). Three patients with aHUS and 4 controls showed elevated C5b-9 deposits on resting cells, which should correspond to active aHUS. None of these patients had laboratory signs of thrombotic microangiopathy (TMA). During follow-up (15.8 months, range: 6-21), estimated glomerular filtration rate remained stable in all. In 5 patients with aHUS with a genetic variant, no increase in C5b-9 deposits was found on activated endothelial cells, which contrasts with the literature suggesting that the test should identify carriers of a genetic variant. CONCLUSION: Our data question the routine use of the ex vivo complement assay in kidney transplant patients. Future studies should evaluate the test characteristics of assay in kidney transplant patients.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Duineveld C, Bouwmeester RN, van den Heuvel LPWJ, et al. Ex Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study. Kidney Int Rep. 2023. PMID: 38312782. doi:10.1016/j.ekir.2023.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。